Liraglutide in obesity: a guide to its use in the EU


    loading  Checking for direct PDF access through Ovid

Abstract

Liraglutide (Saxenda®; 3 mg dose), a glucagon-like peptide-1 receptor agonist, is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index of ≥30 kg/m2 or ≥27 to <30 kg/m2 in the presence of at least one bodyweight-related co-morbidity (e.g. dysglycaemia, dyslipidaemia, hypertension, obstructive sleep apnoea). Clinical data in these patient populations indicates that subcutaneous liraglutide 3.0 mg once daily provides clinically meaningful (i.e. 5-10 % reduction) and sustained reductions in bodyweight and is generally well tolerated.

    loading  Loading Related Articles